Xenetic Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
A share exchange will combine two companies with complementary NET-targeting technologies, creating a unified pipeline across four clinical-stage programs and aiming for leadership in NET therapeutics. The deal is expected to close in Q4 2026, with a European market launch targeted for 2028.
Fiscal Year 2025
-
The meeting was called to order with auditors and legal counsel present, but a quorum was not reached, preventing any business from being conducted. The board will set a new date for the adjourned meeting.
Fiscal Year 2024
-
Preclinical data show DNase I enhances the efficacy of immune checkpoint inhibitors in colorectal cancer models resistant to current therapies. These results support advancing DNase I combinations into clinical development for cancers where NETs drive resistance.